MedTrace Logo

A Long-term Follow-up Study in Participants Who Received CS-101

NCT06685536 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2026-02-10

No results posted yet for this study

Summary

This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-06 (NCT06024876),No investigational drug product will be administered in the study.

Conditions

Interventions

OTHER

Safety and efficacy assessments

Safety evaluations,disease-specific assessments,and assessments to monitor for long-term complications of autologous transplant

Sponsors & Collaborators

  • First Affiliated Hospital of Guangxi Medical University

    collaborator OTHER

  • CorrectSequence Therapeutics Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Yongrong Lai, M.D. · First Affiliated Hospital of Guangxi Medical University

Eligibility

Min Age
6 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-18
Primary Completion
2039-07-31
Completion
2039-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06685536 on ClinicalTrials.gov